Evidence map›Paper›PMID 31086176›Full record

ArticleNature communications2019

An integrated stress response via PKR suppresses HER2+ cancers and improves trastuzumab therapy.

Cedric Darini, Nour Ghaddar, Catherine Chabot, Gloria Assaker, Siham Sabri, Shuo Wang, Jothilatha Krishnamoorthy, Marguerite Buchanan, Adriana Aguilar-Mahecha, Bassam Abdulkarim and 5 more

Open access · goldAbstract read
In one paragraph

Article in Nature communications, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers.

0numbers the graph read from it
0cells of the map it votes in
41citing papers in PubMed
5.6field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

41 citing papers in PubMed, 58 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Review
  8. Mitochondria-Nuclear Crosstalk: Orchestrating mtDNA Maintenance.Environmental and molecular mutagenesis · 2025
    Review
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Review
  17. PKR induces TGF-β and limits oncolytic immune therapy.Journal for immunotherapy of cancer · 2023
    Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 4 institutions in 1 country.

Cedric DariniLady Davis Institute for Medical Research, Sir Mortimer B. Davis-Jewish General Hospital, Montreal, QC, H3T 1E2, Canada.
Nour GhaddarLady Davis Institute for Medical Research, Sir Mortimer B. Davis-Jewish General Hospital, Montreal, QC, H3T 1E2, Canada.
Catherine ChabotLady Davis Institute for Medical Research, Sir Mortimer B. Davis-Jewish General Hospital, Montreal, QC, H3T 1E2, Canada.
Gloria AssakerDepartment of Pathology, Faculty of Medicine, McGill University, Montreal, QC, H3A 2B4, Canada.
Siham SabriDepartment of Pathology, Faculty of Medicine, McGill University, Montreal, QC, H3A 2B4, Canada.
Shuo WangLady Davis Institute for Medical Research, Sir Mortimer B. Davis-Jewish General Hospital, Montreal, QC, H3T 1E2, Canada.
Jothilatha KrishnamoorthyLady Davis Institute for Medical Research, Sir Mortimer B. Davis-Jewish General Hospital, Montreal, QC, H3T 1E2, Canada.
Marguerite BuchananLady Davis Institute for Medical Research, Sir Mortimer B. Davis-Jewish General Hospital, Montreal, QC, H3T 1E2, Canada.
Adriana Aguilar-MahechaLady Davis Institute for Medical Research, Sir Mortimer B. Davis-Jewish General Hospital, Montreal, QC, H3T 1E2, Canada.
Bassam AbdulkarimResearch Institute of McGill University Health Centre, Montreal, QC, H4A 3J1, Canada.
Jean DeschenesDepartment of Laboratory Medicine and Pathology, University of Alberta, Edmonton, AB, T6G 2H7, Canada.
Jose TorresDepartment of Pathology, Faculty of Medicine, McGill University, Montreal, QC, H3A 2B4, Canada.ORCID http://orcid.org/0000-0002-9957-6004
Josie Ursini-SiegelLady Davis Institute for Medical Research, Sir Mortimer B. Davis-Jewish General Hospital, Montreal, QC, H3T 1E2, Canada.
Mark BasikLady Davis Institute for Medical Research, Sir Mortimer B. Davis-Jewish General Hospital, Montreal, QC, H3T 1E2, Canada.
Antonis E KoromilasLady Davis Institute for Medical Research, Sir Mortimer B. Davis-Jewish General Hospital, Montreal, QC, H3T 1E2, Canada. antonis.koromilas@mcgill.ca.
Jewish General Hospital · CAMcGill University Health Centre · CAMcGill University · CAUniversity of Alberta · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Trastuzumab is integral to HER2+ cancer treatment, but its therapeutic index is narrowed by the development of resistance. Phosphorylation of the translation initiation factor eIF2α (eIF2α-P) is the nodal point of the integrated stress response, which promotes survival or death in a context-dependent manner. Here, we show an anti-tumor function of the protein kinase PKR and its substrate eIF2α in a mouse HER2+ breast cancer model. The anti-tumor function depends on the transcription factor ATF4, which upregulates the CDK inhibitor P21

Indexed as

AnimalsAntineoplastic Combined Chemotherapy ProtocolsBiomarkers, TumorBreastBreast NeoplasmsCell Line, TumorDisease ProgressionDrug Resistance, NeoplasmeIF-2 KinaseErb-b2 Receptor Tyrosine KinasesEukaryotic Initiation Factor-2FemaleHumansMiceMice, Inbred NODMice, SCIDBiomarkers, TumorEIF2AK2 protein, humaneIF-2 KinaseERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesEukaryotic Initiation Factor-2Trastuzumab

Identifiers

PMID31086176
PMCPMC6513990
OpenAlexW2946307299

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.